Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Axitinib – Treatment for Advanced Renal Cell Carcinoma

Drug Name (Brand / Generic)

Inlyta / Axitinib

Company / Licensee

Pfizer / SFJ Pharma

Therapy Class

VEGFR inhibitor

Product Description

Multiple tyrosine kinase inhibitor

Current Indication

Advanced renal cell carcinoma

Market Sector

Oncology

Development Status

Approved in the US, Europe and Australia
Expand

Go Top